Biogen-UCB's lupus drug meets main goal of late-stage trial
Corrects executive's name to Meyers from Myers in paragraphs 5 and 6
By Manas Mishra
Sept 24 (Reuters) -Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
The unexpected success, if replicated in a second late-stage study, could offer lupus patients a new alternative in a field littered with trial failures and limited approved therapies. The companies plan to start the second study later this year.
The drug, called dapirolizumab pegol, showed a more significant reduction in disease activity when given along with treatments such as corticosteroids and drugs that suppress the immune system, compared to a placebo in the 321-patient trial, the companies said.
The disease, which mostly affects women, is unpredictable as it causes a range of symptoms. Approved treatments include AstraZeneca's AZN.L Saphnelo and GSK's GSK.L Benlysta.
"There has been substantial progress for our patients, especially with the approval of some of these new therapies. But the reality is, the unmet need remains," Adam Meyers,the head of Biogen's immunology and new disease areas division, said in an interview prior to the data.
"We commonly hear things about modest efficacy or slower onset of action, and our goal is to try to improve upon treatment options for our patients," Meyers added.
The drug is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's immune system attacks the body's own tissues and potentially leads to organ failure.
The disease affects an estimated 200,000 patients in the U.S., according to federal data.
Most Wall Street analysts removed the Biogen-UCB drug from their sales estimates after it failed to meet the main goal of a mid-stage trial in patients with disease that was moderately-to-severely active in 2018.
AstraZeneca's Saphnelo, approved in 2021, made $280 million in 2023 sales, while GSK's Benlysta, which first gained approval in 2011, brought in 1.35 billion euros ($1.50 billion) last year. Several other drugmakers are also developing experimental lupus drugs.
($1 = 0.8991 euros)
Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber and Alan Barona
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
